|
| |
- International symposium on radioiodine. Thyroid 1997; 7: 159-324.
- Nygaard B, Faber J, Hegedüs L, Hansen JM. 131I treatment of
nodular non-toxic goitre. Eur J Endocrinol 1996; 134: 15-20.
- Hermus AdR, Huysmans DA. Treatment of benign nodular thyroid
disease. N Engl J Med 1998; 338: 1438-1447.
- Leech NJ, Dayan CM. Controversies in the management of
Graves’ disease. Clin Endocrinol 1998; 49: 273-280.
- Cooper DS. Radioiodine for hyperthyroidism. Where do we stand
after 50 years? JAMA 1998; 280: 375-376.
- Hall P. Hazards of diagnostic and therapeutic use of radioactive
iodine in thyroid disorders. Thyroid International 1998; 1: 1-14.
- Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High
incidence of multinodular toxic goiter in the elderly population in a low iodine intake
area vs. high incidence of Graves’ disease in the young in a high iodine intake area:
Comparative surveys of thyrotoxicosis epidemiology in East-Jutland, Denmark and Iceland. J
Intern Med 1991; 229: 415-420.
- Wartofsky L, Glinoer D, Solomon B, et al. Differences and
similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan and
the United States. Thyroid 1991; 71: 129-135.
- Nygaard B, Hegedüs L, Gervil M, Hjalgrim H, Hansen BM,
Søe-Jensen P, Hansen JM. Influence of compensated radioiodine therapy on thyroid volume
and incidence of hyperthyroidism in Graves’ disease. J Intern Med 1995; 238: 491-497.
- Hegedüs L, Faber J. Calculation of the ideal dose of
radioiodine for treatment of thyroid disease. Eur J Endocrinol 1995; 132: 544-545.
- Jarløv AE, Hegedüs L, Kristensen LØ, Nygaard B, Hansen JM. Is
calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin
Endocrinol 1995; 43: 325-329.
- Nygaard B, Faber J, Hegedüs L. Acute changes in thyroid volume
and function following 131I therapy of multinodular goitre. Clin Endocrinol 1994; 41:
715-718.
- Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML,
Dell’Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E,
Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves’
ophthalmopathy. N Engl J Med 1998; 338: 73-78.
- Weetman AP, Wiersinga WM. Current management of
thyroid-associated ophthalmopathy in Europe. Results of an international survey. Clin
Endocrinol 1998; 49: 21-28.
- Rivkees SA, Sklar C, Freemark M. The management of Graves’
disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol
Metab 1998; 83: 3767-3776.
- Erickson D, Gharib H, Li H, van Heerden JA. Treatment of
patients with toxic multinodular goiter. Thyroid 1998; 8: 277-282.
- Vanderpump MPJ, Ahlquist JAD, Franklyn JA, Clayton RN. Consensus
statement for good practice and audit measures in the management of hypothyroidism and
hyperthyroidism. Br Med J 1996; 313: 539-544.
- Nygaard B, Hegedüs L, Ulriksen P, Nielsen KG, Hansen JM.
Radioiodine therapy of multinodular toxic goiter. Arch Intern Med 1999; in press.
- Bonnema S, Bertelsen H, Mortensen J, Andersen P, Knudsen DU,
Bastholt L, Hegedüs L. The feasibility of high-dose 131I-treatment as an alternative to
surgery in patients with a monstrous goitre. Effect on thyroid function and size and
pulmonary function. J Endocrinol 1998; 159 (Supplementum): abstract OC18.
- Huysmans DAKC, Hermus Ad RMM, Corstens FHM, Barentsz JO,
Kloppenborg PWC. Large compressive goiters treated with radioiodine. Ann Intern Med 1994;
121: 757-762.
- Nygaard B, Hegedüs L, Gervil M, Hjalgrim H, Søe-Jensen P,
Hansen JM. Radioiodine treatment of multinodular non-toxic goitre. Br Med J 1993; 307:
828-832.
- Nygaard B, Faber J, Veje A, Hegedüs L, Hansen JM. Transition of
nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy. Thyroid
1999; in press.
- Nygaard B, Knudsen JH, Hegedüs L, Veje A, Hansen JEM.
Thyrotropin receptor antibodies and Graves’ disease, a side-effect of 131I treatment
in patients with non-toxic goiter. J Clin Endocrinol Metab 1997; 82: 2926-2930.
- Ferrari C, Reschini E, Paracchi A. Treatment of the autonomous
thyroid nodule: A review. Eur J Endocrinol 1996; 135: 383-390.
- Nygaard B, Hegedüs L, Nielsen KG, Ulriksen P, Hansen JM.
Long-term effect of radioactive iodine on thyroid function and size in patients with
solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol 1999; in press.
- Hegedüs L, Veiergang D, Karstrup S, Hansen JM. Compensated
131I-therapy of solitary autonomous thyroid nodules: Effect on thyroid size and early
hypothyroidism. Acta Endocrinol 1986; 113: 226-232.
- Mariotti S, Martino E, Francesconi M, Ceccarelli C, Grasso L,
Lippi F, Baschieri L, Pinchera A. Serum thyroid autoantibodies as a risk factor for
development of hypothyroidism after radioactive iodine therapy for single thyroid
"hot" nodule. Acta Endocrinol 1986; 113: 500–507.
- Hegedüs L, Bennedbæk FN. Radioiodine for non-toxic diffuse
goitre. Lancet 1997; 350: 409-410.
- Nygaard B, Faber J, Veje A, Hansen JEM. Thyroid volume and
function after 131I treatment of diffuse non-toxic goitre. Clin Endocrinol 1997; 47:
493-496.
- Berghout A, Wiersinga WM, Drexhage HA, Smits NJ, Touber JL.
Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic
non-toxic goitre. Lancet 1990; 336: 193-197.
- Hegedüs L, Nygaard B, Hansen JM. Is routine thyroxine treatment
to hinder postoperative recurrence of non-toxic goiter justified? J Clin Endocrinol Metab
1999; 84: in press.
- Hegedüs L, Hansen BM, Knudsen N, Hansen JM. Reduction of size
of thyroid with radioactive iodine in multinodular non-toxic goitre. Br Med J 1988; 297:
661-662.
- Walfish PG, Caplan D, Rosen IB. Postparathyroidectomy transient
thyrotoxicosis. J Clin Endocrinol Metab 1992; 75: 224-227.
- Bennedbæk FN, Gram J, Hegedüs L. The transition of subacute
thyroiditis to Graves’ disease as evidenced by diagnostic imaging. Thyroid 1996; 6:
457-459.
- Nygaard B, Metcalfe RA, Phipps J, Wetman AP, Hegedüs L.
Graves’ disease and thyroid associated ophthalmopathy triggered by 131I treatment of
non-toxic goiter. J Endocrinol Invest 1999; in press.
- 36. Franklyn JA, Daykin J, Young J, et al. Fine-needle aspiration
cytology in diffuse or multinodular goitre compared with solitary thyroid nodules. Br Med
J 1993; 307: 240.
- Hamburger JI. Evolution of toxicity in solitary nontoxic
autonomously functioning thyroid nodules. J Clin Endocrinol Metab 1980; 50: 1089-1093.
|
|
